229 related articles for article (PubMed ID: 25216514)
1. Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy.
Aichler M; Motschmann M; Jütting U; Luber B; Becker K; Ott K; Lordick F; Langer R; Feith M; Siewert JR; Walch A
Oncotarget; 2014 Aug; 5(16):6620-32. PubMed ID: 25216514
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant chemo-radiotherapy for locally advanced esophageal cancer: a monocentric study.
Schena M; La Rovere E; Solerio D; Bustreo S; Barone C; Daniele L; Buffoni L; Bironzo P; Sapino A; Gasparri G; Ciuffreda L; Ricardi U
Tumori; 2012; 98(4):451-7. PubMed ID: 23052161
[TBL] [Abstract][Full Text] [Related]
3. Perioperative chemotherapy with or without epidermal growth factor receptor blockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: Randomized phase II study with advanced biomarker program of the German Cancer Society (AIO/CAO STO-0801).
Stahl M; Maderer A; Lordick F; Mihaljevic AL; Kanzler S; Hoehler T; Thuss-Patience P; Mönig S; Kunzmann V; Schroll S; Sandermann A; Tannapfel A; Meyer HJ; Schuhmacher C; Wilke H; Moehler M;
Eur J Cancer; 2018 Apr; 93():119-126. PubMed ID: 29501977
[TBL] [Abstract][Full Text] [Related]
4. Prognosis of esophageal squamous cell carcinoma in patients positive for human epidermal growth factor receptor family can be improved by initial chemotherapy with docetaxel, fluorouracil, and cisplatin.
Yamamoto Y; Yamai H; Seike J; Yoshida T; Takechi H; Furukita Y; Kajiura K; Minato T; Bando Y; Tangoku A
Ann Surg Oncol; 2012 Mar; 19(3):757-65. PubMed ID: 21947696
[TBL] [Abstract][Full Text] [Related]
5. Reduced genomic tumor heterogeneity after neoadjuvant chemotherapy is related to favorable outcome in patients with esophageal adenocarcinoma.
Obulkasim A; Ylstra B; van Essen HF; Benner C; Stenning S; Langley R; Allum W; Cunningham D; Inam I; Hewitt LC; West NP; Meijer GA; van de Wiel MA; Grabsch HI
Oncotarget; 2016 Jul; 7(28):44084-44095. PubMed ID: 27286451
[TBL] [Abstract][Full Text] [Related]
6. Thymidylate synthase protein expression: Association with response to neoadjuvant chemotherapy and resection for locally advanced gastric and gastroesophageal adenocarcinoma.
Alexander HR; Grem JL; Hamilton JM; Pass HI; Hong M; Fraker DL; Steinberg SM; McAtee N; Allegra BC; Johnston PG
Cancer J Sci Am; 1995; 1(1):49-54. PubMed ID: 9166454
[TBL] [Abstract][Full Text] [Related]
7. The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group study.
Kandioler D; Schoppmann SF; Zwrtek R; Kappel S; Wolf B; Mittlböck M; Kührer I; Hejna M; Pluschnig U; Ba-Ssalamah A; Wrba F; Zacherl J
J Thorac Cardiovasc Surg; 2014 Nov; 148(5):2280-6. PubMed ID: 25135238
[TBL] [Abstract][Full Text] [Related]
8. Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: Postoperative chemotherapy has a substantial impact on outcome.
Glatz T; Bronsert P; Schäfer M; Kulemann B; Marjanovic G; Sick O; Hopt UT; Zirlik K; Makowiec F; Hoeppner J
Eur J Surg Oncol; 2015 Oct; 41(10):1300-7. PubMed ID: 26253194
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of neoadjuvant and adjuvant chemotherapy with 5-fluorodeoxyuridine, leucovorin, oxaliplatin and docetaxel in the treatment of previously untreated advanced esophageal adenocarcinoma.
Solomon N; Mezentsev D; Reis I; Lima M; Rios J; Avisar E; Franceschi D; Livingstone A; Podolsky L; Ardalan B
Jpn J Clin Oncol; 2011 Apr; 41(4):469-76. PubMed ID: 21258083
[TBL] [Abstract][Full Text] [Related]
10. Clinical response to chemotherapy in oesophageal adenocarcinoma patients is linked to defects in mitochondria.
Aichler M; Elsner M; Ludyga N; Feuchtinger A; Zangen V; Maier SK; Balluff B; Schöne C; Hierber L; Braselmann H; Meding S; Rauser S; Zischka H; Aubele M; Schmitt M; Feith M; Hauck SM; Ueffing M; Langer R; Kuster B; Zitzelsberger H; Höfler H; Walch AK
J Pathol; 2013 Aug; 230(4):410-9. PubMed ID: 23592244
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of 5-fluorouracil, leucovorin, interferon-alpha-2a, and cisplatin as neoadjuvant chemotherapy for locally advanced esophageal carcinoma.
Temeck BK; Liebmann JE; Theodossiou C; Steinberg SM; Cook JA; Metz DC; Shawker TH; Allegra CJ; Russo A; Pass HI
Cancer; 1996 Jun; 77(12):2432-9. PubMed ID: 8640689
[TBL] [Abstract][Full Text] [Related]
12. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.
Pennathur A; Luketich JD; Landreneau RJ; Ward J; Christie NA; Gibson MK; Schuchert M; Cooper K; Land SR; Belani CP
Ann Thorac Surg; 2008 Jun; 85(6):1930-6; discussion 1936-7. PubMed ID: 18498797
[TBL] [Abstract][Full Text] [Related]
13. DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
Ott K; Rachakonda PS; Panzram B; Keller G; Lordick F; Becker K; Langer R; Buechler M; Hemminki K; Kumar R
Ann Surg Oncol; 2011 Sep; 18(9):2688-98. PubMed ID: 21347786
[TBL] [Abstract][Full Text] [Related]
14. The relationship between EGFR gene mutation status and ERCC1 in lung adenocarcinoma of Chinese patients receiving platinum-based neoadjuvant chemotherapy.
Ke HG; Zhou XY; Shen Y; You QS; Yan Y; Shen ZY
Oncol Res; 2012; 20(5-6):221-9. PubMed ID: 23581229
[TBL] [Abstract][Full Text] [Related]
15. Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival.
Kim JS; Kim MA; Kim TM; Lee SH; Kim DW; Im SA; Kim TY; Kim WH; Yang HK; Heo DS; Bang YJ; Lee KU; Choe KJ; Kim NK
Br J Cancer; 2009 Mar; 100(5):732-8. PubMed ID: 19259093
[TBL] [Abstract][Full Text] [Related]
16. Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer.
Tsao MS; Sakurada A; Ding K; Aviel-Ronen S; Ludkovski O; Liu N; Le Maître A; Gandara D; Johnson DH; Rigas JR; Seymour L; Shepherd FA
J Thorac Oncol; 2011 Jan; 6(1):139-47. PubMed ID: 21107284
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of neoadjuvant cisplatin-fluorouracil followed by postoperative intraperitoneal floxuridine-leucovorin in patients with locally advanced gastric cancer.
Brenner B; Shah MA; Karpeh MS; Gonen M; Brennan MF; Coit DG; Klimstra DS; Tang LH; Kelsen DP
Ann Oncol; 2006 Sep; 17(9):1404-11. PubMed ID: 16788003
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemotherapy and surgery for esophageal adenocarcinoma: prognostic value of circumferential resection margin and stratification of N1 category.
Saha AK; Sutton C; Rotimi O; Dexter S; Sue-Ling H; Sarela AI
Ann Surg Oncol; 2009 May; 16(5):1364-70. PubMed ID: 19252949
[TBL] [Abstract][Full Text] [Related]
19. Effect of neoadjuvant chemotherapy on circumferential margin positivity and its impact on prognosis in patients with resectable oesophageal cancer.
Sujendran V; Wheeler J; Baron R; Warren BF; Maynard N
Br J Surg; 2008 Feb; 95(2):191-4. PubMed ID: 17948302
[TBL] [Abstract][Full Text] [Related]
20. Quantitative c-erbB-2 but not c-erbB-1 mRNA expression is a promising marker to predict minor histopathologic response to neoadjuvant radiochemotherapy in oesophageal cancer.
Miyazono F; Metzger R; Warnecke-Eberz U; Baldus SE; Brabender J; Bollschweiler E; Doerfler W; Mueller RP; Dienes HP; Aikou T; Hoelscher AH; Schneider PM
Br J Cancer; 2004 Aug; 91(4):666-72. PubMed ID: 15213712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
